摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N6-[trans-2-(thiophen-2-yl)cyclohex-4-en-yl]adenosine

中文名称
——
中文别名
——
英文名称
N6-[trans-2-(thiophen-2-yl)cyclohex-4-en-yl]adenosine
英文别名
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(1R,6R)-6-thiophen-2-ylcyclohex-3-en-1-yl]amino]purin-9-yl]oxolane-3,4-diol
N6-[trans-2-(thiophen-2-yl)cyclohex-4-en-yl]adenosine化学式
CAS
——
化学式
C20H23N5O4S
mdl
——
分子量
429.5
InChiKey
MMPRIELQKUJNLM-QEMMHZAGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    30
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    154
  • 氢给体数:
    4
  • 氢受体数:
    9

反应信息

  • 作为产物:
    描述:
    (-) trans-2-(thiophen-2-yl)cyclohex-4-enylamine 以 乙醇 为溶剂, 生成 N6-[trans-2-(thiophen-2-yl)cyclohex-4-en-yl]adenosine
    参考文献:
    名称:
    DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
    摘要:
    这项发明涉及[-(1R)-(-)-樟脑磺酸)盐的[1S-[1.alpha.,2.beta.,3.beta.,4.alpha.,(S*)]]-4-[7-[[2-(3-氯-2-噻吩基)-1-乙基乙基]氨基]3 H-咪唑[4,5-b]吡啶-3-基]-N-乙基-2,3-二羟基环戊烷羧酰胺,以及一种制备该化合物的方法,包括将(-)-1.beta.-N-乙基-2.alpha.,3.alpha.-异丙烯基二氧基-4.beta.-[3-氨基-4-[2-(5-氯-2-噻吩基)-(1R)-1-乙基乙基]氨基-2-吡啉基]氨基环戊烷羧酰胺和甲酰胺乙酸盐的反应混合物,然后用(1R)-(-)-樟脑磺酸处理反应混合物。该盐在纯化[1 S-[1.alpha.,2.beta.,3.beta.,4.alpha.,(S*)]]-4-[7-[[2-(3-氯-2-噻吩基)-1-乙基乙基]氨基]-3 H-咪唑[4,5-b]吡啶-3-基]-N-乙基-2,3-二羟基环戊烷羧酰胺方面具有用途,该化合物具有腺苷激动剂活性,并且可用作抗高血压、心脏保护、抗缺血和抗脂解作用剂。
    公开号:
    US05652366A1
点击查看最新优质反应信息

文献信息

  • Compounds having antihypertensive, cardioprotective, anti-ischemic and
    申请人:Rhone-Poulenc Rorer Pharmaceuticals Inc.
    公开号:US05561134A1
    公开(公告)日:1996-10-01
    Compounds of the Formula ##STR1## wherein: K is N or N.fwdarw.O; Q is CH.sub.2 or O; T is ##STR2## or R.sub.3 O--CH.sub.2 ; X is a straight or branched chain alkylene, cycloalkylene or cycloalkenylene group, each of which is optionally substituted by at least one CH.sub.3, CH.sub.3 CH.sub.2, Cl, F, CF.sub.3 or CH.sub.3 O; Y is NR.sub.4, O or S; a=0 or 1; Z is of the formula ##STR3## Z.sub.1 is N, CR.sub.5, (CH).sub.m --CR.sub.5 or (CH).sub.m --N, m being 1 or 2; Z.sub.2 is N, NR.sub.6, O or S, n being 0 or 1; R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are independently H, alkyl, aryl or heterocyclyl; R.sub.a and R.sub.b are independently H, OH, alkyl, hydroxyalkyl, alkyl mercaptyl, thioalkyl, alkoxy, alkyoxyalkyl, amino, alkyl amino, carboxyl, acyl, halogen, carbamoyl, alkyl carbamoyl, aryl or heterocyclyl; and R' and R" are independently hydrogen, alkyl, aralkyl, carbamoyl, alkyl carbamoyl, dialkylcarbamoyl, acyl, alkoxycarbonyl aralkoxycarbonyl, aryloxycarbonyl, or R' and R" together may form ##STR4## where R.sub.c is hydrogen or alkyl, ##STR5## where R.sub.d and R.sub.e are independently hydrogen, alkyl, or together with the carbon atom to which they are attached may form a 1,1-cycloalkyl group; provided that when X is straight chain alkylene and Q is oxygen, then Z represents a heterocyclyl including at least two heteroatoms, which are adenosine agonists useful as antihypertensive, cardioprotective, antiischemic, and antilipolytic agents, pharmaceutical compositions including such compounds, and their use in treating hypertension, myocardial ischemia, ameliorating ischemic injury and myocardial infarct size consequent to myocardial ischemia, hyperlipidemia and hypercholesterolemia are claimed.
    该公式的化合物为##STR1##,其中:K为N或N.fwdarw.O; Q为CH.sub.2或O; T为##STR2##或R.sub.3 O--CH.sub.2; X为直链或支链烷基、环烷基或环烯基,每个基团可以选择性地被至少一个CH.sub.3、CH.sub.3 CH.sub.2、Cl、F、CF.sub.3或CH.sub.3 O取代; Y为NR.sub.4、O或S; a=0或1; Z的化学式为##STR3##Z.sub.1为N、CR.sub.5、(CH).sub.m --CR.sub.5或(CH).sub.m --N,其中m为1或2; Z.sub.2为N、NR.sub.6、O或S,其中n为0或1; R.sub.1、R.sub.2、R.sub.3、R.sub.4、R.sub.5和R.sub.6独立地为H、烷基、芳基或杂环基; R.sub.a和R.sub.b独立地为H、OH、烷基、羟基烷基、烷基硫醇基、硫代烷基、烷氧基、烷氧烷基、氨基、烷基氨基、羧基、酰基、卤素、氨基甲酰基、芳基或杂环基; R'和R"独立地为氢、烷基、芳基烷基、氨基甲酰基、烷基氨基甲酰基、二烷基氨基甲酰基、酰基、烷氧羰基、芳基氧羰基,或R'和R"在一起可以形成##STR4##其中R.sub.c为氢或烷基,##STR5##其中R.sub.d和R.sub.e独立地为氢、烷基,或者与它们连接的碳原子一起可以形成1,1-环烷基; 前提是当X为直链烷基且Q为氧时,Z表示至少包含两个杂原子的杂环基,这些化合物是腺苷受体激动剂,可用作降压、心脏保护、抗缺血和抗脂解剂,包括这些化合物的制药组合物,以及它们用于治疗高血压、心肌缺血、改善因心肌缺血引起的缺血性损伤和心肌梗死大小、高脂血症和高胆固醇血症的用途。
  • DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
    申请人:Rhone-Poulenc Rorer Pharmaceuticals Inc.
    公开号:US05652366A1
    公开(公告)日:1997-07-29
    This invention relates to di[(1 R)-(-)-camphosulfonic acid) salt of [1S-[1.alpha.,2.beta.,3.beta.,4.alpha.,(S*)]]-4-[7-[[2-(3-chloro-2-thienyl )-1-ethylethyl]amino]3 H-imidazo[4,5-b]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentanecarboxamide , and a process for preparing the compound, comprising reacting a reaction mixture of (-)-1.beta.-N-ethyl-2.alpha.,3.alpha.-isopropylidenedioxy-4.beta.-[3-amino -4-[2-(5-chloro-2-thienyl)-(1R)-1-ethylethyl]amino-2-pyridyl]aminocyclopent anecarboxamide and formamidine acetate, and then treating the reaction mixture with (1 R)-(-)-10-camphorsulfonic acid. The salt is useful in purifying [1 S-[1.alpha.,2.beta.,3.beta.,4.alpha.,(S*)]]-4-[7-[[2-(3-chloro-2-thienyl)- 1-ethylethyl]amino]-3 H-imidazo[4,5-b]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentanecarboxamide which possesses adenosine agonist activity and is useful as an anti-hypertensive, cardioprotective, anti-ischemic, and antilipolytic agent.
    这项发明涉及[-(1R)-(-)-樟脑磺酸)盐的[1S-[1.alpha.,2.beta.,3.beta.,4.alpha.,(S*)]]-4-[7-[[2-(3-氯-2-噻吩基)-1-乙基乙基]氨基]3 H-咪唑[4,5-b]吡啶-3-基]-N-乙基-2,3-二羟基环戊烷羧酰胺,以及一种制备该化合物的方法,包括将(-)-1.beta.-N-乙基-2.alpha.,3.alpha.-异丙烯基二氧基-4.beta.-[3-氨基-4-[2-(5-氯-2-噻吩基)-(1R)-1-乙基乙基]氨基-2-吡啉基]氨基环戊烷羧酰胺和甲酰胺乙酸盐的反应混合物,然后用(1R)-(-)-樟脑磺酸处理反应混合物。该盐在纯化[1 S-[1.alpha.,2.beta.,3.beta.,4.alpha.,(S*)]]-4-[7-[[2-(3-氯-2-噻吩基)-1-乙基乙基]氨基]-3 H-咪唑[4,5-b]吡啶-3-基]-N-乙基-2,3-二羟基环戊烷羧酰胺方面具有用途,该化合物具有腺苷激动剂活性,并且可用作抗高血压、心脏保护、抗缺血和抗脂解作用剂。
  • [EN] COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES<br/>[FR] COMPOSES PRESENTANT DES PROPRIETES ANTI-HYPERTENSIVES, CARDIOPROTECTRICES, ANTI-ISCHEMIQUES ET ANTILIPOLYTIQUES
    申请人:RHONE-POULENC RORER PHARMACEUTICALS INC.
    公开号:WO1995028160A1
    公开(公告)日:1995-10-26
    (EN) This invention relates to adenosine derivatives and analogs which possess adenosine agonist activity and are useful as anti-hypertensive, cardioprotective, anti-ischemic, and antilipolytic agents, to pharmaceutical compositions including such compounds, and to their use in treating hypertension, myocardial ischemia, ameliorating ischemic injury and myocardial infarct size consequent to myocardial ischemia, and treating hyperlipidemia and hypercholesterolemia, and to methods and intermediates used in the preparation of such compounds.(FR) La présente invention concerne des dérivés de l'adénosine et analogues qui présentent une activité antagoniste de l'adénosine. Ces composés interviennent dans des compositions pharmaceutiques comme principes anti-hypertenseurs, cardioprotecteurs, anti-ischémiants, et antilipolytiques. Ils permettent de traiter l'hypertension, l'ischémie du myocarde, une évolution favorable des lésions ischémiques et de l'infarctus du myocarde consécutifs à une ischémie du myocarde, et de traiter l'hyperlipidémie et l'hypercholestérolémie. L'invention concerne également des procédés et des intermédiaires utilisés dans la préparation de tels composés.
    该发明涉及腺苷衍生物和类似物,具有腺苷受体激动剂活性,并可用作抗高血压、心脏保护、抗缺血和抗脂肪分解剂,包括这些化合物的制药组合物,以及它们在治疗高血压、心肌缺血、改善心肌缺血所致的缺血性损伤和心肌梗死大小,以及治疗高脂血症和高胆固醇血症方面的应用,以及用于制备这些化合物的方法和中间体。
  • [EN] COMPOUNDS HAVING ANTIHYPERTENSIVE AND ANTI-ISCHEMIC PROPERTIES
    申请人:RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC.
    公开号:WO1992005177A1
    公开(公告)日:1992-04-02
    (EN) This invention relates to adenosine derivatives and analogs which possess adenosine agonist activity and are useful as anti-hypertensive and anti-ischemic agents, to pharmaceutical compositions including such compounds, and to their use in treating hypertension and myocardial ischemia, and to methods and intermediates used in the preparation of such compounds.(FR) On décrit des dérivés et des analogues d'adénosine qui possèdent une activité agoniste de l'adénosine et qui sont utiles en tant qu'agents anti-hypertensifs et anti-ischémiques, des compositions pharmaceutiques comprenant de tels composés, ainsi que leur utilisation dans le traitement de l'hypertension et de l'ischémie myocardique. On décrit en outre les méthodes et les intermédiaires utilisés dans la préparation de tels composés.
    该发明涉及腺苷衍生物和类似物,其具有腺苷受体激动剂活性,并且可用作抗高血压和抗缺血药物,包括这些化合物的药物组合物,以及它们在治疗高血压和心肌缺血方面的应用,以及用于制备这些化合物的方法和中间体。
  • Imidazopyridines having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
    申请人:RHONE-POULENC RORER PHARMACEUTICALS, INC.
    公开号:EP1006115A2
    公开(公告)日:2000-06-07
    This invention relates to adenosine derivatives and analogs which possess adenosine agonist activity and are useful as anti-hypertensive and anti-ischemic agents, to pharmaceutical compositions including such compounds, and to their use in treating hypertension and myocardial ischemia, and to methods and intermediates used in the preparation of such compounds.
    本发明涉及具有腺苷激动剂活性并可用作抗高血压和抗心肌缺血药物的腺苷衍生物和类似物,涉及包括此类化合物的药物组合物,涉及它们在治疗高血压和心肌缺血中的用途,还涉及用于制备此类化合物的方法和中间体。
查看更多